Fujimura T, Yoshino K, Kato H, Fukushima S, et al. Phase II, multicenter study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-PD-1 antibody-refractory malignant melanoma: TM5614-MM trial. Br J Dermatol 2024 Jun 4:ljae231. doi: 10.1093.
PMID: 38833158